Focus Turns To Label After Panel Backs Acadia's Nuplazid
This article was originally published in Scrip
Executive Summary
If the FDA takes its outside experts' advice, Acadia Pharmaceuticals Inc. could finally be on its way to having a billion dollar drug on the US market: Nuplazid (pimavanserin), a selective inverse agonist of the 5-hydroxytryptamine 2A (5-HT2A) receptor, which the biotech is seeking as a treatment for psychosis associated with Parkinson's disease (PDP).